Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody rituximab in patients aged 61 to 80 years with aggressive non-Hodgkin's lymphoma

Next Previous
X
Search
Trial Profile

Randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody rituximab in patients aged 61 to 80 years with aggressive non-Hodgkin's lymphoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Anaplastic large cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Immunoblastic lymphadenopathy; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Primary-Effusion-Lymphoma; T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms RICOVER-60

    • Most Recent Events

    • 01 Apr 2021 Results analyzing the influence of age in pts > 60 years receiving the R-CHOP-14 regimen from RICOVER-60 and consecutive phase-II CHOP-R-ESC trials: DENSE-R-, SMARTE-R-, and SEXIE-R-CHOP-14, published in the Annals of Hematology.
    • 13 Mar 2020 Results comparing International prognostic indices in diffuse large B-cell lymphoma using different trials published in the Blood
    • 12 Dec 2017 Interim results compare patient outcome with the old (fixed) and the new PET-adapted (flexible) treatment strategy, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top